Cipla gains 3% post USFDA approval for its generic HIV drug
newsdepo.com
The stock up 3% at Rs 622 on the BSE in early morning trade and is 6.6% away from its 52-week high of Rs 663 touched on November 7, 2017.Cipla gains 3% post USFDA approval for its generic HIV drug
The stock up 3% at Rs 622 on the BSE in early morning trade and is 6.6% away from its 52-week high of Rs 663 touched on November 7, 2017. Read more